(Q69407236)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:2599802%20AND%20SRC:MED&resulttype=core&format=json

1 October 2019

title

Assessment of N-methylformamide (NMF) administered orally on a three times weekly schedule: a phase I study (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:2599802%20AND%20SRC:MED&resulttype=core&format=json

1 October 2019

author name string

E K Rowinsky

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:2599802%20AND%20SRC:MED&resulttype=core&format=json

1 October 2019

L B Grochow

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:2599802%20AND%20SRC:MED&resulttype=core&format=json

1 October 2019

A Hantel

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:2599802%20AND%20SRC:MED&resulttype=core&format=json

1 October 2019

D S Ettinger

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:2599802%20AND%20SRC:MED&resulttype=core&format=json

1 October 2019

B L Vito

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:2599802%20AND%20SRC:MED&resulttype=core&format=json

1 October 2019

R C Donehower

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:2599802%20AND%20SRC:MED&resulttype=core&format=json

1 October 2019

publication date

1 November 1989

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:2599802%20AND%20SRC:MED&resulttype=core&format=json

Investigational New Drugs

1 October 2019

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:2599802%20AND%20SRC:MED&resulttype=core&format=json

1 October 2019

volume

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:2599802%20AND%20SRC:MED&resulttype=core&format=json

1 October 2019

issue

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:2599802%20AND%20SRC:MED&resulttype=core&format=json

1 October 2019

page(s)

317-325

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:2599802%20AND%20SRC:MED&resulttype=core&format=json

Phase II trial of N-methylformamide for advanced renal cell carcinoma

1 October 2019

cites work

1 reference

12 December 2020

Terminal differentiation of human promyelocytic leukemia cells induced by dimethyl sulfoxide and other polar compounds

1 reference

12 December 2020

N-methylformamide-mediated enhancement of in vitro tumor cell chemosensitivity

1 reference

12 December 2020

Effects of N-methylformamide and related compounds in mouse sarcoma 180.

1 reference

12 December 2020

Phase I trial of N-methylformamide in pediatric patients with refractory leukemias

1 reference

12 December 2020

N-methylformamide-induced hypophosphatemia

1 reference

12 December 2020

N-methylformamide: antitumour activity and metabolism in mice

1 reference

12 December 2020

Phase I study of N-methylformamide in patients with advanced cancer

1 reference

12 December 2020

Phase II study of N-methylformamide, spirogermanium, and 4-demethoxydaunorubicin in the treatment of non-small cell lung cancer (EST 3583): an Eastern Cooperative Oncology Group study

1 reference

12 December 2020

N-Methylformamide (NSC 3051): a potential candidate for combination chemotherapy.

1 reference

12 December 2020

Retardation of growth of Ehrlich ascites tumor by formamides and related compounds

1 reference

12 December 2020

N,N-dimethylformamide-induced modulation of organ- and tumor-associated markers in cultured human colon carcinoma cells

1 reference

12 December 2020

Phase II study on oral N-methylformamide in metastatic colorectal cancer

1 reference

12 December 2020

The antitumour effect and toxicity of cis-platinum and N-methylformamide in combination

1 reference

12 December 2020

Phase I trial of N-methylformamide (NMF, NSC 3051).

1 reference

12 December 2020

Induction of erythroid differentiation in murine virus infected eythroleukemia cells by highly polar compounds

1 reference

12 December 2020

Toxicity and response criteria of the Eastern Cooperative Oncology Group

1 reference

12 December 2020

Radiosensitization of primary human tumor cell cultures by N-methylformamide

1 reference

12 December 2020

Clinical Pharmacology of Oral and Iv N-Methylformamide: A Pharmacologic Basis for Lack of Clinical Antineoplastic Activity

1 reference

12 December 2020

Toxicity of oral N-methylformamide in three phase II trials: a report from the National Cancer Institute of Canada Clinical Trials Group.

1 reference

12 December 2020

The hepatotoxic action of N-methylformamide in man

1 reference

12 December 2020

Modification of tumor and normal tissue radioresponse in mice by N-methylformamide

1 reference

12 December 2020

Phase II study of N-methylformamide in patients with advanced colorectal cancer

1 reference

12 December 2020

N,N-dimethylformamide-induced alteration of cell culture characteristics and loss of tumorigenicity in cultured human colon carcinoma cells

1 reference

12 December 2020

Polar solvents: a novel class of antineoplastic agents

1 reference

12 December 2020

A model for quantitation of peritumoral brain edema

1 reference

12 December 2020

Phase I trial of N-methylformamide

1 reference

12 December 2020

Phase II trial of N-methylformamide in advanced head and neck cancer

1 reference

12 December 2020

Studies of the pharmacology of N-methylformamide in mice

1 reference

12 December 2020